New combo therapy aims to tame immunotherapy side effects
NCT ID NCT06841705
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding vedolizumab (Entyvio) to a short course of steroids works better than standard steroids alone for colitis caused by immune checkpoint inhibitors. About 80 adults with grade 2-3 diarrhea will receive either vedolizumab plus a short steroid taper or a placebo plus a longer steroid taper. The goal is to see if more patients achieve steroid-free remission at 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vedolizumab (Entyvio) and prednisone
- What this could lead to
- If it works, this could offer a faster, steroid-sparing treatment for colitis caused by cancer immunotherapy, reducing side effects from long-term steroid use.
- What could go wrong
- This is a small, early-phase trial (80 people). The drug may not improve remission rates, and vedolizumab carries risks like infusion reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States